A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease.
The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:
Chimeric Antigen Receptors Targeting the Gamma Delta (γδ) T-Cell Receptor
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a set of Chimeric Antigen Receptors (CARs) that target the γδ T-Cell Receptor.
Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia
Summary:
The NCI seeks research co-development partners or licensees for Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia.
Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
Summary:
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium-Derived Factor (PEDF) peptide as a gene-agnostic approach to treating inherited retinal diseases.
Fluorinated MU-Opioid Receptor Agonists
Summary:
Investigators at the National Institute on Drug Abuse seek co-development partners and/or licensees for collection of mu opioid receptor (MOR) agonists as alternatives for existing compounds.
Description of Technology:
Although existing opioids are excellent analgesics and useful as positron emission tomography (PET) radiotracers, they come with debilitating side effects. These include addiction, respiratory distress, hyperalgesia, and constipation. Therefore, there is a need for alternatives with lower adverse effects.
Suppression Of Uveitis By A STAT3 Single Domain Antibody
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for a STAT3 antibody that can suppress uveitis.
TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A.
Using Artificial Intelligence To Diagnose Uveitis
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for a deep learning algorithm that can identify retinal vasculitis using color fundus images.
Description of Technology:
Uveitis is caused by inflammation in the eye that can cause pain and reduce vision. The rate of uveitis in the United States is 1 in every 200 people with eye-related irritation. Permanent symptoms such as vision loss can occur if untreated. Therefore, early detection is crucial.
Improved Methods For Cryopreservation Of Cells, Tissues, And Organs
Summary:
The National Eye Institute seeks research co-development partners and/or licensees for novel methods of cryopreserving cells, tissues, and organs via FOXO1 activation and other mechanisms.